

Drug Monograph

Drug/Drug **DermacinRx Lidotral[®] (lidocaine hydrochloride) cream/**
 Class: **Topical Anesthetic**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	DermacinRx Lidotral [®] is available as a cream that contains 3.88% lidocaine hydrochloride respectively.	
Manufacturer:	PureTek Corporation, San Fernando, CA 91340	
Indications:	DermacinRx Lidotral [®] is for the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites, and minor skin irritation.	
Costs:	\$1,407.60 per 85 gram tube of DermacinRx Lidotral [®] . Wholesale Acquisition Cost	
Summary of Findings:	The MO HealthNet Division recommends prior authorization status for this product.	
Status Recommendation:	<input checked="" type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
	<input type="checkbox"/> Fiscal Edit	<input type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE	<input type="checkbox"/> Under Solicitation
	<input checked="" type="checkbox"/> Appropriate Indications	<input type="checkbox"/> No PA Required

Prepared By: Luke Boehmer Pharm.D.
 Date: November 18, 2016